Interferon alpha for the treatment of advanced renal cancer

被引：8
作者：
Ravaud, A
Dilhuydy, MS
机构：
[1] CHU Bordeaux, Hop St Andre, Dept Med Oncol & Radiotherapy, F-33075 Bordeaux, France
[2] Univ Bordeaux Victor Segalen II, Bordeaux, France
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2005年 / 5卷 / 06期
基金：
英国医学研究理事会;
关键词：
immunotherapy; interferon alpha; metastatic renal cell carcinoma; renal cell carcinoma;
D O I：
10.1517/14712598.5.6.749
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
This paper is an overview on the place of IFN-alpha in metastatic renal cell carcinoma (MRCC). After a presentation of MRCC and the mode of action of IFN-alpha the results of studies including IFN-alpha alone or in combination with IL-2, chemotherapy and other biological modifiers are presented. Finally, new trends for new drugs, including antiangiogenic therapies, are discussed.
引用
收藏
页码：749 / 762
页数：14
相关论文
共 122 条
[1]  
AAPRO MS, 1983, CANCER CHEMOTH PHARM, V10, P161
[2]   Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha interferon in patients with metastatic renal cell cancer: a phase II study [J].
Allen, MJ ;
Vaughan, M ;
Webb, A ;
Johnston, S ;
Savage, P ;
Eisen, T ;
Bate, S ;
Moore, J ;
Ahern, R ;
Gore, ME .
BRITISH JOURNAL OF CANCER, 2000, 83 (08) :980-985
[3]   THE EFFECT OF ALPHA-INTERFERON AND GAMMA-INTERFERON ON CELL-GROWTH AND HISTOCOMPATIBILITY ANTIGEN EXPRESSION BY HUMAN RENAL-CARCINOMA CELLS IN-VITRO [J].
ANGUS, R ;
COLLINS, CMP ;
SYMES, MO .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (13) :1879-1885
[4]  
[Anonymous], CANC PRINCIPLES PRAC
[5]   RANDOMIZED PHASE-II TRIAL OF HIGH-DOSE INTERLEUKIN-2 EITHER ALONE OR IN COMBINATION WITH INTERFERON-ALFA-2B IN ADVANCED RENAL-CELL CARCINOMA [J].
ATKINS, MB ;
SPARANO, J ;
FISHER, RI ;
WEISS, GR ;
MARGOLIN, KA ;
FINK, KI ;
RUBINSTEIN, L ;
LOUIE, A ;
MIER, JW ;
GUCALP, R ;
SOSMAN, JA ;
BOLDT, DH ;
DOROSHOW, JH ;
ARONSON, FR ;
SZNOL, M .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :661-670
[6]   Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].
Atkins, MB ;
Hidalgo, M ;
Stadler, WM ;
Logan, TF ;
Dutcher, JP ;
Hudes, GR ;
Park, Y ;
Lion, SH ;
Marshall, B ;
Boni, JP ;
Dukart, G ;
Sherman, ML .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918
[7]   Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma:: A prospectively German cooperative renal randomized trial of the carcinoma chemoimmunotherapy group (DGCIN) [J].
Atzpodien, J ;
Kirchner, H ;
Jonas, U ;
Bergmann, L ;
Schott, H ;
Heynemann, H ;
Fornara, P ;
Loening, SA ;
Roigas, J ;
Müller, SC ;
Bodenstein, H ;
Pomer, S ;
Metzner, B ;
Rebmann, U ;
Oberneder, R ;
Siebels, M ;
Wandert, T ;
Puchberger, T ;
Reitz, M .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1188-1194
[8]   MULTIINSTITUTIONAL HOME-THERAPY TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-2 AND INTERFERON ALFA-2 IN PROGRESSIVE METASTATIC RENAL-CELL CARCINOMA [J].
ATZPODIEN, J ;
HANNINEN, EL ;
KIRCHNER, H ;
BODENSTEIN, H ;
PFREUNDSCHUH, M ;
REBMANN, U ;
METZNER, B ;
ILLIGER, HJ ;
JAKSE, G ;
NIESEL, T ;
SCHOLZ, HJ ;
WILHELM, S ;
PIELMEIER, T ;
ZAKRZEWSKI, G ;
BLUM, G ;
BEIER, J ;
MULLER, GW ;
DUENSING, S ;
ANTON, P ;
ALLHOFF, E ;
JONAS, U ;
POLIWODA, H .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) :497-501
[9]  
ATZPODIEN J, 1999, SEMIN ONCOL S9, V20, P22
[10]   A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma [J].
Berg, WJ ;
Schwartz, LH ;
Amsterdam, A ;
Mazumdar, M ;
Vlamis, V ;
Law, TM ;
Nanus, DM ;
Motzer, RJ .
INVESTIGATIONAL NEW DRUGS, 1997, 15 (04) :353-355
12345678910